A recent trial has found that Ivonescimab, a newly developed dual-action drug, significantly improves survival rates for patients with advanced squamous non-small cell lung cancer when combined with chemotherapy. Patients treated with Ivonescimab lived an average of 28 months, compared to 24 months for those receiving another immunotherapy, tislelizumab, marking a 15% increase in survival. This investigational treatment works by disabling the tumor's ability to evade the immune system and targeting proteins that facilitate tumor growth. The study, published in The Lancet, included 532 participants in China and is being presented at the American Society of Clinical Oncology annual meeting in Chicago. While experts have described these findings as a promising advancement, they emphasize the need for further research to understand the long-term benefits and risks associated with this treatment. Lung cancer remains a leading health issue in the UK, with around 32,800 deaths annually, making it the most common cause of cancer-related deaths in the country.